2016-002243-42: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin,HuMax®-AXL-ADC) in patients with solid tumors. |
|
|
| Not yet recruiting | 1/2 | 426 | Europe | enapotamab vedotin, IgG1-1021-107-MMAE, Powder for concentrate for solution for infusion | Genmab A/S, Genmab A/S | Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma, Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung or skin, Diseases [C] - Cancer [C04] | | | | |
